- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03616236
Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment
March 6, 2024 updated by: Friends Research Institute, Inc.
This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program.
Project implementation will occur at Guilford Avenue, the primary intake unit for Baltimore City Community Supervision (Probation and Parole).
The proposed study is a parallel two-group randomized controlled trial in which 160 men and 160 women with OUD on community supervision in Baltimore will be randomly assigned within community supervision status (probation or parole) and gender to one of two treatment conditions: (1) Buprenorphine Bridge Treatment (BBT): Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment; or (2) Treatment as Usual (TAU): Participants will receive a referral to buprenorphine treatment in the community.
Both conditions will receive information on overdose prevention.
Participants will be assessed at baseline, and 1, 2, 3, 6, and 12 months post-intake using a comprehensive assessment battery.
The Primary Aim: To compare the relative effectiveness of BBT to TAU in terms of: (a) illicit opioid drug test (oral saliva) results.
The Secondary Aim: To examine the extent to which BBT is superior to TAU in terms of: (b) number of days receiving opioid treatment; (c) number of days using illicit opioids; (d) quality of life (i.
physical health; ii.
mental health); (e) HIV risk behaviors (i.
sexual behavior; ii.
needle use or sharing); (f) criminal activity; (g) re-arrest; and (h) re-incarceration.
The proposed study is significant because the large number of probationers/parolees with OUD have limited access to an efficacious treatment, buprenorphine pharmacotherapy.
The proposed study is innovative because it would be the first trial in the US assessing the effectiveness of interim buprenorphine initiated at a community supervision office compared to referral to a community treatment program.
The public health impact would be widespread, as this model of care could be scaled-up throughout many areas of the US with criminal justice populations with high rates of OUD.
Study Type
Interventional
Enrollment (Estimated)
320
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael S Gordon, DPA
- Phone Number: 251 410-837-3977
- Email: mgordon@friendsresearch.org
Study Contact Backup
- Name: Frank J Vocci, PhD
- Phone Number: 255 410-837-3977
- Email: fvocci@friendsresearch.org
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21202
- Recruiting
- Division of Parole & Probation
-
Contact:
- Michael Gordon
- Phone Number: 251 410-837-3977
- Email: mgordon@friendsresearch.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Subject must provide written informed consent prior to the conduct of any study-related procedures
- Male or female, 18-65 years of age, inclusive
- Be on parole or probation for at least the next 4 months
- Have a Baltimore City address, and (5) Primary diagnosis of (DSM-5) moderate-severe opioid use disorder (at least 4 symptoms) including current use and current physiologic dependence [Note: parolees not currently physically dependent will be allowed in the study].
Exclusion Criteria:
- Current medical condition that may prevent the participant from safely participating in the study as determined by medical evaluation
- Current psychosis or suicidal ideation
- Cognitive disorders that prevent the participant from passing a study enrollment quiz
- Any pending legal action that would interrupt study participation (eg, pending incarceration, probation/parole revocation, unadjudicated charges)
- Exposure to any investigational drug within 8 weeks of screening
- Current use benzodiazepines (such as Valium, Xanax and other sedatives), either prescribed or illicitly obtained
- Currently enrolled in a methadone maintenance treatment program or taking long-acting naltrexone.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: TAU
Participants will receive a referral to buprenorphine treatment in the community.
|
Participants will receive a referral to buprenorphine treatment in the community
Other Names:
|
Experimental: BBT
Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
|
Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
opioid use
Time Frame: 12 months
|
illicit opioid drug test (oral saliva) results
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
treatment adherence
Time Frame: 12 months
|
entered community based treatment
|
12 months
|
treatment adherence
Time Frame: 12 months
|
number of days receiving opioid treatment
|
12 months
|
opioid use days
Time Frame: 12 months
|
number of days using illicit opioids
|
12 months
|
health-related quality of life
Time Frame: 12 months
|
physical health using the SF-12 Health Survey
|
12 months
|
health-related quality of life
Time Frame: 12 months
|
mental health using the SF-12 Health Survey
|
12 months
|
HIV risk behaviors
Time Frame: 12 months
|
sexual behavior using the Risk Assessment Battery (RAB)
|
12 months
|
HIV risk behaviors
Time Frame: 12 months
|
needle use or sharing using the Risk Assessment Battery (RB)
|
12 months
|
criminal activity
Time Frame: 12 months
|
criminal activity days
|
12 months
|
re-arrest
Time Frame: 12 months
|
time to re-arrest
|
12 months
|
re-incarceration
Time Frame: 12 months
|
time to re-incarceration
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
July 20, 2018
First Submitted That Met QC Criteria
July 31, 2018
First Posted (Actual)
August 6, 2018
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FRI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
FRI is committed to the open and timely dissemination of research outcomes.
Investigators in the proposed activity recognize that promising new methods and strategies may arise during the course of the research.
Fri will abide by the principles for sharing research resources as described by NIH in "Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.
Working with the research community, as well as the federal funding agency, FRI will serve the scientific community at large by sharing ideas and software to ensure that new knowledge benefits society.
Our goals are to disseminate new ideas so the public can benefit from discoveries, and to generate new ideas for research and education.
Any data shared will be de-identified and follow the regulations set forth in applicable Human Subjects Protection Guidelines.
IPD Sharing Time Frame
At completion of the study.
IPD Sharing Access Criteria
Contact Dr. Michael Gordon Friends Research Institute
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use
-
Sharon WalshNational Institute on Drug Abuse (NIDA)Completed
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Indonesia UniversityRecruiting
-
Lawson Health Research InstituteNot yet recruiting
-
University of Colorado, DenverUniversity of Nebraska; Agency for Healthcare Research and Quality (AHRQ)Completed
-
Zulekha HospitalsCompleted
-
Peking University People's HospitalCompleted
-
University of UtahCompleted
-
University Health Network, TorontoOntario Ministry of Health and Long Term CareCompleted
Clinical Trials on Treatment as usual
-
Universitätsklinikum Hamburg-EppendorfCompletedPerioperative AnxietyGermany
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
McMaster UniversityNot yet recruiting
-
Gaia AGRecruitingType 2 DiabetesGermany
-
Centre for Addiction and Mental HealthCompleted
-
King's College LondonUnknown
-
University Hospital, AkershusUniversity of OsloActive, not recruiting
-
University of IndianapolisUniversity of Missouri, Kansas City; Missouri State UniversityCompletedHypertension | Diabete Type 2United States
-
Universitat Jaume IConsorcio Hospitalario Provincial de CastellónCompletedDepression | AnxietySpain
-
Kuopio University HospitalUniversity of Oslo; University of Eastern Finland; City of KuopioRecruiting